Detalhe da pesquisa
1.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer
; 127(23): 4421-4431, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424530
2.
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
BMC Cancer
; 14: 69, 2014 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24498872
3.
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Am J Hematol
; 90(7): E139-41, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25858582
4.
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk
; 16(3): 139-45, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26775883
5.
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk
; 14(1): 68-72, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24220616
6.
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
J Clin Oncol
; 30(21): 2670-7, 2012 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689805